成立年份: 2022
总资产(USD): 不愿意公开
员工总人数: 10人以下
主要竞争优势: 品牌,国际认证/标准,接受小额订单,良好的信誉,优质服务
其他竞争优势:
专利与版权:
业务类型:
年销售额(USD): 不愿意公开
主要销售市场: 北美洲
主要产品类别: 药品制剂
所有产品:
外销比重:
内销比重:
主要客户:
合同定制:
付款条款:
At Mullan, we are committed to expanding access to safe and effective medications worldwide. With over 1,200 FDA-approved products, we are currently focused on serving the US market, but we plan to register them in more markets in the future as part of our ongoing mission to benefit patients across the globe.
Mullan was founded in 2022 as a subsidiary of Pasaca Capital. As a Pasaca company, we are committed to serving the global community by creating value through our business. Pasaca’s expertise in distribution and operations, combined with a strong capital base and extensive global network, provide us with the resources we need to pursue our vision.
800EColoradoBlvd.Suite888,Pasadena,CA